Atomwise unveils Chagas disease compounds from AIMS program

Atomwise has revealed the first hit identifications by two of its AIMS program collaborators, including compounds against an unexploited target for Chagas disease, for which there are few therapies.

On Tuesday, Atomwise Inc. (San Francisco, Calif.) and the Drugs for Neglected Diseases initiative (DNDi) announced the discovery of compounds targeting Trypanosoma cruzi, which causes Chagas disease...